About Us

HAHN-JUN LEE M.Sc., Ph.D.

Hahn-Jun Lee, M.Sc., Ph.D. is a serial entrepreneur who founded Epygenix Therapeutics, Inc. which develops precision medicines for rare and intractable pediatric genetic epilepsies. He also founded Polaryx Therapeutics, Inc which develops patient-friendly medicines for lysosomal storage disorders and Focus Therapeutics, L.L.C., a business catalyst in the biotech-pharma industry. He also co-founded Curyx Partners, LLC, a drug development platform.

He has extensive experiences in R&D, deal making, business development, and consulting several top-notch health care venture capital firms and global pharma and biotech companies, including Doman Associates, Shire Human Genetic Therapies, P&G Pharma, Melior Discovery, CDI, etc. He also consulted with several Korean biotechs, venture capital firms, and research institutes.

Dr. Lee was an Assistant Professor of Biotechnology in the Department of Orthopedic Surgery, College of Physicians and Surgeons, Columbia University in the City of New York. He also worked as a Staff Scientist at the RIKEN Brain Science Institute in Japan.

He obtained a B.S. in Life Science from Sogang University, Seoul, Korea. He completed his M.S. and Ph.D. in applied biotechnology in the Department of Applied Biotechnology at the University of Tokyo, Japan.

ANTHONY LAM CFA, CPA

Anthony Lam Anthony Lam has over 20 years of experience in private equity investing. He was Chief Investment Officer of Transpac Capital Limited, one of the earliest pan-Asian venture capital/private equity platforms in the region. Before joining Transpac, Mr. Lam was one of the Founding Managing Directors and Head of China at Asia Climate Partners, the largest climate related private equity fund in the region. Prior to Asia Climate Partners, he was Managing Director and Co-Head Asia Pacific of TRG Management, The Rohatyn Group. Mr. Lam served on the global investment committee and managed a portfolio of seven investee companies with a total investment amount of over $600 million in China, Singapore, South Korea as well as Thailand. Prior to joining TRG, Mr. Lam was a Partner at Citigroup Venture Capital International, the private equity arm of Citigroup, with cumulative AUM over US $6 billion. During his tenure at Citigroup, Mr. Lam had led or actively participated in private equity transactions in a variety of industries including healthcare, renewable energy, financial, consumer, retail, telecommunication, industrial and technology. Mr. Lam received his M.B.A. from the Chinese University of Hong Kong and is a Chartered Financial Analyst and Certified Public Accountant-Inactive.

LUIS A ROJAS, M.Sc., Ph.D.

Luis Rojas, M.Sc., Ph.D. is a research scientist statistician with approximately 35 years of experience that expands to the pharmaceutical, CRO, academic and medical device industries.

As the Head of Biometrics at Epygenix, he supports protocol development and all biometrics activities.

Dr. Rojas is a Subject Matter Expert in Study Design, Master Protocols, RWD/RWE, Bioequivalence, Advanced Analytics (missing data, testing strategies, modeling, simulations, data mining and machine learning), interim analysis, data monitoring committees, the process for converting clinical data into CDISC compliant datasets, and reporting to regulatory agencies.

He holds a Ph.D. in Biostatistics from the Rafael Belloso University in Venezuela, and he is a member of the American Statistical Association, The Sigma Xi Scientific Research Society, and a member of the DIA Adaptive Design Scientific Working Group.  He has published several papers and presented in multiple settings worldwide topics associated with Rare Diseases, adaptive designs, RWE/RWD, the estimand and other clinical research/biostatistics topics.

COLLEEN JOHNSON M.Sc., D.A.B.T

Colleen Johnson, M.S., D.A.B.T is a board-certified toxicologist who has been working with small- to mid-sized pharmaceuticals companies for more than 20 years. Her focus has primarily been in small molecule development for a broad range of indications. She is involved in providing toxicology expertise for all phases of development from early discovery to NDA and BLA applications. She received her undergraduate training at the University of California Santa Barbara and her graduate training at the University of Arizona. Colleen has overseen all aspects of the nonclinical development program on behalf of Epygenix Therapeutics Inc.

Dr. Kalipada Pahan, Ph.D

Dr. Pahan is a Professor of Neurological Sciences, Biochemistry and Pharmacology and the Floyd A. Davis, M.D., Endowed Chair in Neurology at the Rush University Medical Center in Chicago. He is also a Veterans Affairs Scientist at the Jesse Brown VA Medical Center. Currently, he is engaged in translational biomedical research involving Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, and Batten Dsease. He is the Editor-in-Chief of the Journal of Multiple Sclerosis, Senior Editor of the Journal of Neuroimmune Pharmacology, Editor of three other journals, and a chartered member of the Clinical Neuroimmunology and Brain Tumors study section at the NIH.

He has over 160 publications and is cited by Wikipedia. He received the outstanding teaching award in 2000, the “Chancellor’s Council Silver U Award” in 2004 and the "Reinhardt Research Scholar Award” in 2005 from the University of Nebraska Medical Center. Recently he also received VA merit awards from the US Department of Veterans Affairs and the Zenith award from the Alzheimer’s Association.

Dr. Hynda Kleinman, Ph.D.

Hynda K. Kleinman received an MS and a Ph.D from Massachusetts Institute of Technology in 1971 and 1974, respectively. After a postdoctoral fellowship at Tufts University from 1973-1975, she directed a research lab at the NIH from 1975-2006. She has published over 430 papers and has 9 patents, 2 of which have been successfully commercialized. Matrigel is used worldwide for various in vitro/in vivo assays and was among the top 15 NIH patents bearing royalties for many years. The regenerative protein thymosin beta 4 is currently in phase 3 trials for ocular injuries. She has received numerous national/international awards for her scientific accomplishments, including the Hildegard Doerenkamp-Gerhardt Zbinden Award for developing “an in vitro assay for screening anti-cancer compounds which spares animals”. She received the Debio Peptide Award for identifying a peptide which inhibits cancer growth and metastases, the WISE (Women in Science and Engineering) Award for “being the most outstanding woman scientist in the federal government”, and the Senior Woman in Science Award from the American Society for Cell Biology for “her scientific achievement and strong commitment to the fostering of women in science.” She is currently a consultant to various biotech companies, including Bioqual Inc, Polaryx® Therapeutics, RegeneRx Biopharmaceuticals, Inc., and etc.

Dr. Raymond Wang, M.D.

Dr. Raymond Wang, M.D. is the Director of the Multidisciplinary Lysosomal Storage Disorder Program at CHOC Children’s Hospital and a board certified clinical geneticist and biochemical genetics specialist. Dr. Wang is aware of the challenges faced by patients and families with rare diseases such as lysosomal storage disorders. He has committed the program to provide: treatment for the lysosomal disorders that have existing therapies; access to investigational treatment for patients with disorders that currently have no approved / effective therapy, and translational research vital to development of “next generation” treatments and cures for lysosomal storage disorder patients. He has participated in clinical trials for Type 2 Neuronal Ceroid Lipofuscinosis, Pompe Disease, Niemann-Pick C Disease, and Mucopolysaccharidoses. He also is the principal investigator for translational research involving gene therapy and gene editing for treatment of lysosomal storage disorders.

Dr. Wang graduated from Stanford University with Honors and Distinction in Biological Sciences. He earned his medical degree from the University of California, Los Angeles (UCLA), and completed his internship and residency in medical genetics and pediatrics at Cedars-Sinai Medical Center where he served as chief resident in his final year of training. Dr. Wang completed his fellowship in biochemical genetics at the UCLA Intercampus Medical Genetics Program. In 2006, Dr. Wang received the American College of Medical Genetics and Genzyme Fellowship in Biochemical Genetics Award and the Cedars-Sinai Medical Center’s Paul Rubenstein Prize for Excellence in Resident Research. Dr. Wang has been named an Orange County Clinical Biochemical Genetics Physician of Excellence in 2015, 2016, 2017, 2018, and 2019 and nominated for a 2018 Global Genes RARE Champion of Hope Award for his work with children with rare metabolic conditions.

Dr. Angela Schulz, M.D., Ph.D.

Dr. Jonathan W. Mink, M.D. Ph.D., FAAN, FANA, FAAP

ALEX YANG J.D., L.L.M.

Andrew O.